Lymphoma Treatment Program

The Lymphoma Treatment Program at the Hyundai Cancer Institute at CHOC provides its patients with the non-Hodgkin lymphoma, Hodgkin lymphoma and recurrent lymphomas with the latest treatments available. Each treatment is customized to meet the specific needs of the patient while also balancing the social and emotional needs of the patient and family. Treatments are based on the type and stage of the lymphoma, as well as the most current national and international protocols and research available.

Our lymphoma team knows that a cancer diagnosis can be stressful and frightening. Our specialists are dedicated to providing the care, compassion and open communication patients and their families need. As part of their dedication, they make sure that all new patients are seen within 24 to 48 hours of being referred by their physician.

What We Treat

We treat all types of lymphoma:

• Hodgkin lymphoma
• Non-Hodgkin lymphoma (including diffuse large B-cell lymphoma, anaplastic large cell lymphoma, Burkitt lymphoma, primary mediastinal B-cell lymphoma, lymphoblastic lymphoma, grey zone lymphoma, peripheral T-cell lymphoma, NK-cell lymphoma, cutaneous T-cell lymphoma and other rare types of pediatric lymphomas)

Clinical Trials and Research

The experts at the Hyundai Cancer Institute at CHOC provide the very latest treatments and engage in innovative research furthering the advancement of treatment both for now and in the future.

Children’s cancers are very different than adult cancers and must be treated with specific pediatric cancer protocols. Our experience in exclusively treating children, adolescents and young adults (AYA) makes us the experts in the evaluation and treatment of all forms of common childhood and AYA cancers. We are dedicated to administering the very latest pediatric cancer treatment options. A majority of our treatment protocols come from the Children’s Oncology Group (COG), a national organization funded by the National Cancer Institute (NCI). We are also a member of several multi-institutional consortia that offer innovative treatments of pediatric lymphomas. Several pharma industries sponsored clinical trials for lymphomas are open at CHOC as well. In addition, we are offering individualized treatment approaches for patients with rare or unusual types of lymphomas or refractory disease.

Learn more about our ongoing research and the clinical trials available at the Cancer Institute.